LRRC56 Inhibitors
LRRC56 inhibitors encompass a spectrum of compounds that exert their effects by targeting specific cellular signaling pathways which can indirectly influence the functional activity of LRRC56. For example, LY294002 and Wortmannin are potent inhibitors of PI3K, a kinase critical for the activation of the AKT signaling pathway. Inhibition of PI3K by these compounds disrupts AKT-mediated signaling cascades, which could result in a diminished functional activity of LRRC56, presuming LRRC56 is a downstream target of this pathway. Through the cessation of PI3K activity, these inhibitors effectively reduce the phosphorylation of multiple downstream effector proteins, potentially including LRRC56, thus attenuating the protein's functional activity.
Compounds such as PD98059 and U0126 offer another mechanism for inhibiting LRRC56 by targeting the MAPK/ERK signaling pathway. These inhibitors selectively bind to MEK1/2, preventing the activation of ERK1/2 kinases. If LRRC56 is regulated via the ERK pathway, hindering MEK would lead to a decrease in LRRC56 activity by reducing the phosphorylation and activation of proteins in this pathway. Similarly, SB203580 and SP600125 inhibit the p38 MAPKand JNK MAPK pathways, respectively. By impeding these kinases, the associated stress and inflammatory response pathways are downregulated, which may contribute to an indirect reduction in LRRC56 activity if it is responsive to these signaling events. Inhibition of these pathways can result in the alteration of the phosphorylation status of numerous proteins, potentially influencing the activity of LRRC56.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, LY294002 binds to the ATP-binding site of PI3K, preventing its kinase activity. PI3K is involved in the PI3K/AKT pathway, which, when inhibited, results in reduced phosphorylation of downstream targets, including possibly LRRC56, if it were a downstream effector. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, Wortmannin irreversibly binds to PI3K, leading to the cessation of its lipid kinase activity. This blockade can reduce AKT activation and thus downstream signaling that may involve LRRC56. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1/2, PD98059 binds to the inactive forms of MEK1/2, preventing their activation by upstream kinases. By inhibiting MEK, the ERK pathway is downregulated, potentially inhibiting LRRC56 if it is an ERK pathway target. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1 and MEK2, resulting in the blockade of ERK1/2 activation. If LRRC56 activity is mediated through the ERK pathway, its functional activity would be indirectly inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound selectively inhibits p38 MAP kinase. By inhibiting p38, SB203580 can reduce the response to stress signals that might involve LRRC56 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 prevents the phosphorylation and activation of JNK. The inhibition of JNK signaling can decrease the activity of proteins modulated by this stress-activated pathway, potentially including LRRC56. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR, a key protein in the PI3K/AKT pathway. mTOR inhibition can lead to reduced protein synthesis and could indirectly inhibit LRRC56 if it's under mTOR control. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG490 is a selective inhibitor of the JAK/STAT pathway. By inhibiting JAK2, it prevents the phosphorylation and activation of STATs, potentially reducing the activity of LRRC56 if it is regulated by STAT signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that targets Bcr-Abl and Src family kinases. By inhibiting these kinases, Dasatinib could decrease the activation of downstream pathways that may regulate LRRC56. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits EGFR tyrosine kinase, which could reduce signaling through pathways that involve EGFR and potentially decrease the activity of LRRC56 if it is affected by EGFR signaling. | ||||||